ANTIBODIES SPECIFICALLY BINDING TYPE 1 RECEPTOR OF FIBROBLAST GROWTH FACTOR, ANTIBODIES APPLICATION FOR ONCOLOGICAL DISEASE TREATMENT, METHOD FOR ANTIBODIES PRODUCTION Russian patent published in 2017 - IPC C07K16/28 A61K39/395 A61P35/00 C12N15/13 C12N5/10 

FIELD: biotechnology.

SUBSTANCE: antibodies of the invention specifically bind and block the type 1 receptor of fibroblast growth factor (FGFR1) and are characterized by amino acid sequences of H-CDR1, H-CDR2, H-CDR3, L-CDR1, L-CDR2 and L-CDR3. A pharmaceutical composition for oncological diseases treatment comprising the antibodies of the invention is provided, and a method for oncological diseases treatment, comprising administration of the antibodies of the invention to the patient. A method for antibodies production encoding their nucleic acids and cell lines for antibodies production is also provided.

EFFECT: inventions allow to suppress tumour cells proliferation with high efficiency and specificity and inhibit tumour angiogenesis by blocking the pathological pathway, which in turn allows effective treatment of oncological diseases.

22 cl, 5 tbl, 5 ex